These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 34523893)

  • 1. Remdesivir (Veklury) for the Treatment of COVID-19 in Hospitalized Patients.
    Odeti S; Yellepeddi VK
    Am Fam Physician; 2021 Sep; 104(3):311-312. PubMed ID: 34523893
    [No Abstract]   [Full Text] [Related]  

  • 2. Update Alert 2: Remdesivir for Adults With COVID-19.
    Kaka AS; MacDonald R; Linskens EJ; Wilt TJ
    Ann Intern Med; 2021 Dec; 174(12):W114-W115. PubMed ID: 34606312
    [No Abstract]   [Full Text] [Related]  

  • 3. Update Alert 2: Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2).
    Qaseem A; Yost J; Etxeandia-Ikobaltzeta I; Abraham GM; Jokela JA; Miller MC; Forciea MA; Humphrey LL;
    Ann Intern Med; 2021 Dec; 174(12):W116-W117. PubMed ID: 34606308
    [No Abstract]   [Full Text] [Related]  

  • 4. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1).
    Qaseem A; Yost J; Etxeandia-Ikobaltzeta I; Abraham GM; Jokela JA; Forciea MA; Miller MC; Humphrey LL; ; Centor RM; Andrews R; Haeme R; Kansagara DL; Marcucci M
    Ann Intern Med; 2021 Feb; 174(2):229-236. PubMed ID: 33017175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remdesivir (Veklury) for COVID-19.
    Med Lett Drugs Ther; 2020 Nov; 62(1612):186-188. PubMed ID: 33443491
    [No Abstract]   [Full Text] [Related]  

  • 6. COVID-19 updates: Remdesivir (Veklury) in high-risk outpatients with COVID-19.
    Med Lett Drugs Ther; 2022 Feb; 64(1644):31-32. PubMed ID: 35171898
    [No Abstract]   [Full Text] [Related]  

  • 7. Remdesivir as a broad-spectrum antiviral drug against COVID-19.
    Hong YN; Xu J; Sasa GBK; Zhou KX; Ding XF
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):541-548. PubMed ID: 33506946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.
    Wu TY; Chen PY; Wang JT; Liu WD; Chen YC; Chang SC
    J Antimicrob Chemother; 2024 May; 79(5):1196-1200. PubMed ID: 38538154
    [No Abstract]   [Full Text] [Related]  

  • 9. Comment on: Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.
    Barone F; Giacomelli A; Casalini G; Corbellino M; Lai A; Gori A; Antinori S
    J Antimicrob Chemother; 2024 Sep; 79(9):2400-2402. PubMed ID: 39073825
    [No Abstract]   [Full Text] [Related]  

  • 10. Audio Interview: New Data on Remdesivir in Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 May; 382(22):e94. PubMed ID: 32459948
    [No Abstract]   [Full Text] [Related]  

  • 11. Timing of remdesivir for COVID-19.
    Med Lett Drugs Ther; 2020 Oct; 62(1609):161. PubMed ID: 33429407
    [No Abstract]   [Full Text] [Related]  

  • 12. Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2.
    Williamson BN; Pérez-Pérez L; Schwarz B; Feldmann F; Holbrook MG; Singh M; Lye DS; Babusis D; Subramanian R; Haddock E; Okumura A; Hanley PW; Lovaglio J; Bosio CM; Porter DP; Cihlar T; Mackman RL; Saturday G; de Wit E
    Antiviral Res; 2022 Feb; 198():105246. PubMed ID: 35032523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of early remdesivir administration in COVID-19 disease progression in hospitalised patients.
    Platzer M; Totschnig D; Karolyi M; Clodi-Seitz T; Wenisch C; Zoufaly A
    Wien Klin Wochenschr; 2024 Aug; 136(15-16):458-464. PubMed ID: 38884783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remdesivir for Adults With COVID-19 : A Living Systematic Review for American College of Physicians Practice Points.
    Wilt TJ; Kaka AS; MacDonald R; Greer N; Obley A; Duan-Porter W
    Ann Intern Med; 2021 Feb; 174(2):209-220. PubMed ID: 33017170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remdesivir Approved to Treat COVID-19 Amid Controversy.
    Aschenbrenner DS
    Am J Nurs; 2021 Jan; 121(1):22-24. PubMed ID: 33350691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remdesivir: a pendulum in a pandemic.
    Schwartz IS; Heil EL; McCreary EK
    BMJ; 2020 Nov; 371():m4560. PubMed ID: 33234523
    [No Abstract]   [Full Text] [Related]  

  • 17. Assessing the evidence on remdesivir.
    Trøseid M; Hites M; Barratt-Due A; Ader F; Yazdanpanah Y
    Lancet Infect Dis; 2021 Dec; 21(12):1630-1631. PubMed ID: 34838222
    [No Abstract]   [Full Text] [Related]  

  • 18. Developing statewide remdesivir use criteria.
    Fox ER; Shah M; Vinik R; Brown S; Buckel W; Webb B; Zarndt J; Evans M; Mesdaghi P; Imlay HN; Spivak ES
    Am J Health Syst Pharm; 2021 Mar; 78(8):732-735. PubMed ID: 33483744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir.
    Camprubí D; Gaya A; Marcos MA; Martí-Soler H; Soriano A; Mosquera MDM; Oliver A; Santos M; Muñoz J; García-Vidal C
    Int J Infect Dis; 2021 Mar; 104():379-381. PubMed ID: 33359065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2).
    Qaseem A; Yost J; Etxeandia-Ikobaltzeta I; Abraham GM; Jokela JA; Forciea MA; Miller MC; Humphrey LL; ; Centor RM; Andrews R; Haeme R
    Ann Intern Med; 2021 May; 174(5):673-679. PubMed ID: 33560862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.